12th Alzheimer’s & Parkinson’s Drug Development Summit

This Event has Passed

Tuesday, April 23, 2024 - 9:00 AM
to Thursday, April 25, 2024 - 5:00 PM

Add to Calendar

04/23/2024 09:00 AM 04/25/2024 05:00 PM America/Anguilla 12th Alzheimer’s & Parkinson’s Drug Development Summit After a 17-year hiatus in drug approvals for neurodegeneration, disease-modifying drugs for AD have finally broken the ice. With Lecanemab’s clinically proven 30% reduction in cognitive decline receiving the green light from the FDA & PMDA and Eli Lilly’s Donanemab hot on their heels for approval, 58 new trials entering the pipeline this year, and the alpha-synuclein self-seeding assay changing the game for PD drug development. The 12th Alzheimer’s & Parkinson’s Drug Development Summit is indisputably the ultimate industry-focused meeting dedicated to sharing the hottest unpublished AD & PD research from senior biopharma KOLs you won’t hear anywhere else, with deep-dive content a... Details & Tickets: https://www.upcomingevents.com/boston/events/hilton-boston-logan-airport/12th-alzheimers-parkinsons-drug-development-summit-149806?ref=uceaddevent Hilton Boston Logan Airport, One Hotel Drive, Boston, MA, 02128

Neighborhoods

East Boston (Boston)
Haymarket (Boston)
North End (Boston)
South Boston (Boston)

View Event Website »

After a 17-year hiatus in drug approvals for neurodegeneration, disease-modifying drugs for AD have finally broken the ice. With Lecanemab’s clinically proven 30% reduction in cognitive decline receiving the green light from the FDA & PMDA and Eli Lilly’s Donanemab hot on their heels for approval, 58 new trials entering the pipeline this year, and the alpha-synuclein self-seeding assay changing the game for PD drug development. The 12th Alzheimer’s & Parkinson’s Drug Development Summit is indisputably the ultimate industry-focused meeting dedicated to sharing the hottest unpublished AD & PD research from senior biopharma KOLs you won’t hear anywhere else, with deep-dive content all the way from early discovery through to late phase trials and approvals. This April, join 150+ senior industry leaders across discovery, preclinical, biomarker, translational, clinical, and commercial this year from Eli Lilly, Biogen, Eisai, Abbvie, Merck, Michael J. Fox Foundation, Acumen, Vigil Neuroscience, and many more….

Event Links

Website: https://go.evvnt.com/2146026-0

Tickets: https://go.evvnt.com/2146026-2

Brochure: https://go.evvnt.com/2146026-3

View Less